Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neurocrine Biosciences (NBIX) -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (741)	5/29/2001 12:34:37 AM
From: Spekulatius	Read Replies (1) \| Respond to of 1834

>> A research premium of about 800M, price to book of 6...... my how times change! One of the premier research organizations in the world, advancing therapies for a number of diseases, and it's regarded as expensive at a market cap of under $1 billion. Sheesh. << I guess I am a "vulture investor" and like it dirt cheap, even if its a bit smelly. Thanks for the perspective, Rick! One of the issues with LT biotech investing is that the risk perception does change enormously. Many Biotech stocks seems to get cheap once in a while. I just bet on that this will happen again soon - I still think that we are basically in a bear market and that this might affect the Biotechs once again. I intend to be ready for this day with a large cash position.